As Her Oral Contraceptive Needs Change, Her Source Doesn't Have To
Making Informed Choices
A Choice For Nursing Mothers
Watson Choices In Oral Contraceptives
Contact Us
Oral Contraceptives Home
Search Go
Physician Prescribing Information
Patient Prescribing Information  
- The first therapeutic bioequivalent to Triphasil®*1
  • Pharmacokinetic studies demonstrate bioequivalence throughout all three phases†1
First tablet sequence:
Second tablet sequence:
Third tablet sequence:
- Optimal packaging for ease-of-patient use
  • Easy-to-use credit-card pill pack


Women who use oral contraceptives (OCs) should be strongly advised not to smoke due to the increased risk of cardiovascular side effects. Serious risks reported with the use of OCs include blood clots, stroke, and heart attacks. OCs are contraindicated in women with thrombophlebitis, thromboembolic disorders, breast cancer, hepatic or estrogen-dependent neoplasia, cerebrovascular or coronary artery disease, jaundice, or undiagnosed genital bleeding. OCs do not protect against HIV infection (AIDS) or other sexually transmitted diseases.

Please see full Prescribing Information.
†Based on the results of open-label, randomized pharmacokinetic studies repeated at intervals of at least 4 weeks.
Reference: 1. Data on file, Watson Pharma, Inc.
*Brand names are the trademarks of the products' manufacturers and/or owners.
**Products illustrated may not appear at actual size and/or exact color.
Watson Pharmaceuticals, Inc.

Copyright © 2003 - 2015 Watson Pharma, Inc. All rights reserved.
Terms of Use
Legal/Copyright Disclaimer Privacy Policy
This site is intended for US residents only. Site Last Updated: 2010-12-17